Estrategias Combinadas en Inmunoterapia Traslacional
ITC
Netherlands Cancer Institute
Amsterda, HolandaPublicaciones en colaboración con investigadores/as de Netherlands Cancer Institute (16)
2024
-
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Nature Communications, Vol. 15, Núm. 1
-
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641
-
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors
Clinical Cancer Research, Vol. 30, Núm. 13, pp. 2693-2701
2023
-
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022
Annals of Oncology, Vol. 34, Núm. 1, pp. 48-60
2021
-
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC
Journal of Thoracic Oncology
-
OX40 agonist BMS-986178 alone or in combination with nivolumab and/or ipilimumab in patients with advanced solid tumors
Clinical Cancer Research, Vol. 27, Núm. 2, pp. 460-472
-
Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma
European Urology Focus, Vol. 7, Núm. 5, pp. 1084-1091
2020
-
Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1‒positive, advanced non‒small-cell lung cancer in the KEYNOTE-010 study
Journal of Clinical Oncology, Vol. 38, Núm. 14, pp. 1580-1591
2019
-
Corrigendum re: “Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens” (European Urology (2018) 73(3) (462–468), (S0302283817310151) (10.1016/j.eururo.2017.11.023))
European Urology
-
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: An updated analysis of keynote-010 trial
Annals of Oncology, Vol. 30, Núm. 2, pp. 281-289
2018
-
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens
European Urology, Vol. 73, Núm. 3, pp. 462-468
-
Starting the fight in the tumor: Expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)
Annals of Oncology, Vol. 29, Núm. 11, pp. 2163-2174
2017
-
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
The Lancet, Vol. 389, Núm. 10064, pp. 67-76
2016
-
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
The Lancet, Vol. 387, Núm. 10031, pp. 1909-1920
-
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial
The Lancet, Vol. 387, Núm. 10027, pp. 1540-1550
2015
-
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Nature Reviews Cancer, Vol. 15, Núm. 8, pp. 457-472